Skip to main content
. 2024 Mar 19;15:1287504. doi: 10.3389/fimmu.2024.1287504

Figure 2.

Figure 2

Binding antibody serum levels against Omicron subvariant BA.1 spike in research assays and correlation with protection against SARS-CoV-2 post-vaccine infection. (A) Correlation between research assay anti-S (WT) IgG serum levels (BAU/mL) and research assay anti-S (BA.1) IgG serum levels (AU/mL) in 171 samples (Spearman ρ = 0.8411; p < 0.0001). (B) Comparison of anti-S (BA.1) IgG serum levels between the uninfected group and the post-vaccine infection (PVI) group. p-Values determined using the Mann–Whitney U test (p = 0.04). (C) Correlation between research assay anti-S (BA.1) IgG serum levels (AU/mL) and total FLU-PRO plus symptom scores (n = 31; Spearman ρ = −0.34; p = 0.0613). (D) Correlation between research assay anti-S (BA.1) IgG serum levels (AU/mL) and total symptom duration of any symptom in days (n = 31; Spearman ρ = −0.4597; p = 0.0093). Dots indicate results from individual participants. *p < 0.05.